Lipoprotein(a), smoking, and diabetes are additive but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome Authors: Gregory G. Schwartz, Michael Szarek, Vera A. Bittner, Deepak L. Bhatt, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, Ghada Hassan, J. Wouter Jukema, Irena Stevanovic, Hagai Tavori, Samantha Thielen, Harvey D. White, P. Gabriel Steg Published: 2027 Lipoprotein(a) is a genetically validated, independent risk factor for myocardial infarction, ischemic stroke, peripheral artery disease, and need for arterial revascularization procedures. This is believed to be due to a combination of atherogenic, inflammatory, and pro-thrombotic effects of elevated lipoprotein(a) [1]. The acquired, common factors of smoking and diabetes mellitus are also thought to convey cardiovascular risk through a similar triad of atherogenic, inflammatory, and pro-thrombotic mechanisms [2,3]. Whether lipoprotein(a), smoking, and diabetes are additive or interactive (synergistic) risk factors is unknown and might influence the urgency and intensity of risk factor management. We addressed this question in a post hoc analysis of the ODYSSEY OUTCOMES trial (clinicaltrials.gov NCT01663402), an international randomized, double-blind, placebo-controlled evaluation of the effects of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on major adverse cardiovascular events (MACE) in 18,924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite high-intensity or maximum tolerated statin treatment [4]. All participants provided written informed consent. The trial was approved by the institutional review board or ethics committee at each site. In previous univariate analysis, elevated lipoprotein(a) increased the risk of the primary MACE endpoint (coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, and hospitalization for unstable angina) and ischemia-driven coronary revascularization in the placebo group and was associated with larger absolute and relative reductions in that risk with alirocumab [5]. Similarly, diabetes was associated with the risk of MACE in the placebo group and with absolute reduction in that risk with alirocumab [6]. An association of smoking with the risk of MACE in the placebo group and risk reduction with alirocumab has not been investigated previously. In the present analysis, we determined the 4-year Kaplan Meier incidence of MACE in the placebo group and the reduction in MACE by alirocumab according to the presence or absence of these three risk factors, each considered dichotomously: lipoprotein(a) at its median value, prevalent diabetes, and smoking (current vs previous or never) at the time of randomization. We examined an expanded MACE endpoint (comprising all cardiovascular deaths and ischemia-driven coronary revascularization in addition to non-fatal myocardial infarction, ischemic stroke, and hospitalization for unstable angina) since each component was directly associated with lipoprotein(a) levels and/or reduced by alirocumab. Cox regression models adjusted for age, sex, geographic region, low density lipoprotein cholesterol (LDL-C), and systolic blood pressure were used to evaluate the association of Lp(a) quartile with MACE, without or with further adjustment for smoking and diabetes. Lipoprotein(a) was measured in mass concentration by an immunoturbidometric assay with rabbit polyclonal anti-Lp(a) detection antibody and inter-assay coefficient of variation 3.1–4.8% depending on Lp(a) concentration (Siemens, Healthcare Diagnostics, Malvern, PA, USA). Baseline characteristics of the ODYSSEY OUTCOMES trial population have been previously published [4] and include mean age 58.5 years; 25.2% female sex; and enrollment in Central or Eastern Europe (28.7%), Western Europe (22.0%), Canada or United States (15.2%), Latin America (13.7%), Asia (12.1%), or other parts of the world (8.3%). The prevalence of diabetes [6] was 28.8% (of whom 99.3% had type 2 and 0.7% had type 1 diabetes) and 24.1% were active smokers at the time of enrollment. Mean systolic blood pressure was 128 mmHg. Median (quartile [Q] 1, Q3) LDL-C and lipoprotein(a) were 87 (73, 104) and 21.2 (7, 60) mg/dL, respectively. Patients were followed for median (Q1, Q3) 2.8 (2.3, 3.4) years. The 4-year Kaplan Meier incidence of the expanded MACE endpoint was 19.7% (1474 events) in the placebo group and 17.4% (1301 events) in the alirocumab group (hazard ratio [HR] 0.87; 95% confidence interval [CI] 0.81, 0.94). In the placebo group (n = 9462), Lp(a) ≥median was associated with greater risk of MACE than Lp(a)